公开(公告)号：EP1881844A2

公开(公告)日：2008-01-30

申请号：EP06727137.9

申请日：2006-05-18

申请人： GlaxoSmithKline Biologicals s.a.

发明人： DEWERCHIN, Marianne

IPC分类号： A61K39/02

CPC分类号： A61K39/0258 ,  Y02A50/474

摘要： The present invention provides a vaccine composition comprising the B-subunit of E. coli heat labile toxin or a derivative thereof with equal or greater than 90% homology complexed with an antigen and an adjuvant.

公开(公告)号：EP1877426A2

公开(公告)日：2008-01-16

申请号：EP06753523.7

申请日：2006-04-27

申请人： GlaxoSmithKline Biologicals SA ,  INFECTIOUS DISEASE RESEARCH INSTITUTE (IDRI)

发明人： COLER, Rhea, Infectious Disease Research Institute ,  LOBET, Yves, GlaxoSmithKline Biologicals s.a. ,  REED, Steven, Infectious Disease Research Inst.

IPC分类号： C07K14/35 ,  A61K39/04

CPC分类号： A61K39/04 ,  A61K31/4409 ,  A61K31/496 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/575 ,  C07K14/35

摘要： The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

公开(公告)号：EP1868641A2

公开(公告)日：2007-12-26

申请号：EP06739529.3

申请日：2006-03-24

申请人： GlaxoSmithKline Biologicals SA ,  CORIXA CORPORATION

发明人： BARTH, Brenda ,  BHATIA, Ajay ,  ALDERSON, Mark ,  MAISONNEUVE, Jean-Francois L. ,  LOBET, Yves ,  NOZAY, Florence, Bernadette ,  MARCHAND, Martine ,  METTENS, Pascal ,  SKEIKY, Yasir A. ,  PROBST, Peter

IPC分类号： A61K39/118

CPC分类号： A61K39/118 ,  A61K2039/55572 ,  A61K2039/55577 ,  C07K14/295

摘要： The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.

公开(公告)号：EP1009430B1

公开(公告)日：2006-11-15

申请号：EP98950005.3

申请日：1998-09-02

申请人： GlaxoSmithKline Biologicals S.A.

发明人： GARCON, Nathalie ,  MOMIN, Patricia, Marie, Christine, Aline, François

IPC分类号： A61K39/39 ,  A61K9/107 ,  A61K47/28

CPC分类号： A61K39/39 ,  A61K9/0019 ,  A61K47/28 ,  A61K2039/55511 ,  A61K2039/55566 ,  A61K2039/55577 ,  Y02A50/412 ,  Y10S514/937 ,  Y10S514/938 ,  Y10S514/943

摘要： The present inventions relates to an oil in water emulsion compositions, their use in medicine, in particular to their u

公开(公告)号：EP1032669B1

公开(公告)日：2006-02-08

申请号：EP98965170.8

申请日：1998-11-16

申请人： Glaxosmithkline Biologicals S.A.

发明人： BRUCK, Claudine ,  BOLLEN, Alex ,  JACOBS, Paul ,  MASSAER, Marc

IPC分类号： C12N15/12 ,  C07K14/435 ,  A61K39/35

CPC分类号： C07K14/43531 ,  C12N9/6472

摘要： The present invention provides a novel treatment for allergy comprising the provision of a recombinant allergen with reduced enzymatic activity. Vaccines comprising said mutant allergens stimulate a Th1-type immune response in allergic or naïve individuals, thereby reducing the potential for an allergic response upon contact with wild-type allergen. Preferably said allergen is DerP1.

公开(公告)号：EP1528914A1

公开(公告)日：2005-05-11

申请号：EP03787793.3

申请日：2003-08-12

申请人： GlaxoSmithKline Biologicals S.A.

发明人： VANDE VELDE, V.GlaxoSmithKline Biologicals S.A.

IPC分类号： A61K9/00 ,  A61K9/19 ,  A61K47/26

CPC分类号： A61K47/26 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/02 ,  Y02A50/385 ,  Y02A50/411 ,  Y02A50/463 ,  Y02A50/481

摘要： The present invention relates to novel antigenic compositions suitable for parenteral and mucosal administration, comprising an antigen within an aqueous medium and a carbohydrate, wherein the carbohydrate is in the form of a derivative which exhibits acidic moieties, preferably in the form of its carboxylic acid derivative. The antigenic compositions are in a stable solid form and, after reconstitution with a liquid excipient or adjuvant followed by administration through the parenteral or mucosal route, rapidly dissolve in the body fluids, thereby releasing the reconstituted vaccine into the body. Specifically, the lyophilized form may consist of a powder or a cake containing the antigen, preferably in an amorphous (glassy) state, which is formed from a liquid solution or suspension by drying or sublimation, preferably sublimation by lyophilisation.

公开(公告)号：EP1162993B1

公开(公告)日：2005-04-06

申请号：EP00907633.2

申请日：2000-02-28

申请人： GlaxoSmithKline Biologicals S.A.

发明人： VINALS y de BASSOLS, Carlota

IPC分类号： A61K38/17 ,  A61K39/395 ,  C07K14/705 ,  A61P35/00 ,  A61K39/00 ,  A61K48/00 ,  C07K16/28 ,  G01N33/68 ,  C12Q1/68 ,  C12N15/12

CPC分类号： A61K39/0011 ,  A61K48/00 ,  C07K14/705

公开(公告)号：EP1432442A2

公开(公告)日：2004-06-30

申请号：EP02777259.9

申请日：2002-09-30

申请人： GlaxoSmithKline Biologicals S.A.

发明人： GARCON, N.;c/o GlaxoSmithKline Beecham Bio.

IPC分类号： A61K39/39 ,  A61K9/127 ,  A61K9/00

CPC分类号： A61K39/39 ,  A61K9/0021 ,  A61K9/127 ,  A61K31/706 ,  A61K45/06 ,  A61K2039/54 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/55577 ,  Y02A50/386 ,  Y02A50/412 ,  A61K2300/00

摘要： The present invention provides novel intradermal vaccines and novel uses for adjuvants in the preparation of intradermal vaccines, and also novel methods of treatment comprising them. The intradermal adjuvants, and methods, of the present invention comprise a saponin and a sterol, wherein the saponin and sterol are formulated in a liposome. The intradermal adjuvants are used in the manufacture of intradermal vaccines for humans, and in the intradermal treatment of humans.

公开(公告)号：EP0868918B1

公开(公告)日：2004-04-28

申请号：EP98201308.8

申请日：1994-12-20

申请人： GlaxoSmithKline Biologicals S.A.

发明人： Momin, Patricia Marie ,  Garcon, Marie-Josephe

IPC分类号： A61K39/39

CPC分类号： A61K39/39 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  Y02A50/412

摘要： The present invention provides vaccine compositions comprising an oil in water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of a range of immune responses.

公开(公告)号：EP1383534A2

公开(公告)日：2004-01-28

申请号：EP02712901.4

申请日：2002-02-08

申请人： Glaxosmithkline Biologicals S.A.

发明人： BERTHET, F-X Jacqueline,GlaxoSmithKline Bio S.A. ,  LOBET, Yves,GlaxoSmithKline Biologicals S.A. ,  POOLMAN, Jan,GlaxoSmithKline Biologicals S.A. ,  VERLANT, Vincent,GlaxoSmithKline Biological S.A.

IPC分类号： A61K39/116 ,  A61P31/04

CPC分类号： C07K14/295 ,  A61K39/00 ,  A61K39/118

摘要： The present invention relates to the field of Gram-negative bacterial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to the field of useful Gram-negative bacterial outer membrane vesicle (or bleb) compositions comprising heterologously expressed Chlamydia antigens, and advantageous methods of rendering these compositions more effective and safer as a vaccine.